In May 2014, the FDA astutely stated that any decision to use aspirin should be an individual clinical judgement by health-care providers. Almost simultaneously, the MESA investigators formulated, but did not test, a hypothesis that coronary artery calcification scoring might aid health-care providers in making this judgement.
References
US Department of Health and Human Services. FDA. Can an aspirin a day help prevent a heart attack? [online], (2014).
Miedema, M. D. et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the Multi-Ethnic Study of Atherosclerosis. Circ. Cardiovasc. Qual. Outcomes 7, 453–460 (2014).
Hennekens, C. H. Increasing global burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 97, 1095–1102 (1998).
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 324, 71–86 (2002).
Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 373, 1849–1860 (2009).
Hennekens, C. H. & D'Agostino, R. B. Global risk assessment for cardiovascular disease and astute clinical judgement. Eur. Heart J. 8, 12–13 (2003).
Hennekens, C. H. & Gelb, I. J. Utilization of statins: guiding principles and the new United States guidelines. Cardiology 128, 41–42 (2014).
Hennekens, C. H. & Baigent C. Prevention: Aspirin in primary prevention—good news and bad news. Nat. Rev. Cardiol. 9, 262–263 (2012).
Hennekens, C. H. & DeMets, D. Statistical association and causation: contributions of different types of evidence. JAMA 306, 1134–1136 (2011).
Hennekens, C. H. et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysis. Arch. Intern. Med. 164, 40–44 (2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.H.H. declares that he serves as an independent scientist in an advisory role to investigators and sponsors as chairman or a member of Data and Safety Monitoring Boards for: Amgen, Bayer, British Heart Foundation, Cadila, Canadian Institutes of Health Research, FDA, Lilly, Genzyme, NIH, Pfizer, Sanofi, Sunovion, UpToDate, and the Wellcome Foundation; and to legal counsel for GlaxoSmithKline. He receives royalties for authorship or editorship of three textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital. He has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority and does not own any common or preferred stock in any pharmaceutical or medical device company.
D.L.D. declares that he is partially supported by an NIH grant to the University of Wisconsin for the Clinical Translational Science Award for statistical consultation and collaboration and administrative leadership. He serves or has recently served as an independent biostatistician in an advisory role to investigators and sponsors often as a member of independent Data and Safety Monitoring Boards for: Actelion, Amgen, Astellas, AstraZeneca, Biotronik, Boehringer-Ingelheim, CVRx, the Duke Clinical Research Institute, Genentech, GlaxoSmithKline, Harvard Partner's, Merck, Millennium, Novartis, Pfizer, the Population Health Research Institute of McMaster University Roche, Sanofi Aventis, and Takeda. He receives royalties from publishers of the three textbooks that he has coauthored and edited; has tax-sheltered retirement accounts in mutual funds with Fidelity and Morgan Stanley; and has a small account of stock with Intel.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Hennekens, C., DeMets, D. Aspirin in primary prevention needs individual judgements. Nat Rev Cardiol 11, 438–440 (2014). https://doi.org/10.1038/nrcardio.2014.88
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.88
- Springer Nature Limited
This article is cited by
-
Aspirin for primary prevention of cardiovascular disease
Thrombosis Journal (2015)